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screening may reduce the annual number of stillbirths by up to 2,900, neonatal 
deaths by up to 1,100, the annual incidence of congenital syphilis by up to 1,450 and 
avert up to 130,000 DALYs at an incremental annual direct medical cost of US$ 5.9 
million. The three relatively high prevalence countries of Brazil, Colombia and Haiti, 
account for over half of the total DALYs that could potentially be averted, whereas 
Chile and Cuba have already adopted universal screening. ConClusions: Use of 
ICS tests for antenatal syphilis screening is highly cost-effective in low and middle 
income countries in Latin America. Antenatal programs should either expand access 
or maintain full access to syphilis screening using the ICS test.
PIH36
Cost-EffECtIvEnEss AnAlysIs of CoffEE ConsumPtIon for PrEvEntIon 
of All-CAusE mortAlIty In tHE unItEd stAtEs
Campbell C.M., Popelar BV, Dandappanavar AS, Knight JM, O’Day K., Xcenda L.L.C.
Palm Harbor, FL, USA
objeCtives: Coffee (Coffea arabica) contains over 1,000 distinct molecular compounds 
and is one of the most widely consumed beverages worldwide. Epidemiologic stud-
ies have shown an inverse relationship between coffee consumption and all-cause 
mortality. This analysis aims to assess the cost-effectiveness of coffee from the 
perspective of the US consumer and payer. Methods: A cohort life-table analysis 
was developed to model life-years (LYs) of US coffee consumers vs non-consumers 
over a lifetime horizon. Age- and gender-specific mortality rates were used to model 
survival outcomes. Relative risks of death by average coffee intake (cups/day) were 
obtained from a recent large, prospective US cohort study. Costs per cup were esti-
mated for home preparation and obtained from a national sample of low- and high-
cost vendors. Incremental analyses were conducted by cost, sex, and level of daily 
coffee consumption. Deterministic (DSA) and probabilistic (PSA) sensitivity analy-
ses were conducted. The model was validated by comparing life expectancy results 
to a model utilizing relative risks of cancer and chronic diseases based on coffee 
consumption. Results: Coffee increased undiscounted LYs in 1, 2-3, 4-5, and 6+ 
cup/day male (0.72, 1.23, 1.48, and 1.22) and female (0.53, 1.42, 1.77, 1.65) consumers, 
respectively, versus non-consumers. ICERs per discounted LY gained were $5,460, 
$11,326, $24,254 for males and $5,885, $8,910, $20,145 for females, respectively, for 
1, 2-3, and 4-5 cups/day consumption of home-prepared coffee; 6+ cups/day was 
strictly dominated. Consumption of 4-5 cups per day purchased from high-cost ven-
dors was not cost-effective, with ICERs > $50,000/LY-gained. DSA showed that coffee 
effectiveness in preventing death and coffee acquisition cost had the largest impact 
on ICERs. ConClusions: In this analysis, coffee consumption was associated with 
increased LYs and was shown to be potentially cost-effective, especially if home-
prepared or purchased from low-cost vendors. Given the observational nature of the 
study data, further research is warranted to validate these findings.
PIH37
Cost EffECtIvEnEss AnAlysIs of tHE usE of HumAn fIbrInogEn 
(ClottAfACt®) In mAsIvE Post-PArtum HEmorrAgEA In mExICo
Contreras I.1, Maldonado D.2, Gomez S.3, Olvera S.2, Dupuis R.4
1Instituto Mexicano del Seguro Social, México City, Mexico, 2Innovare R&D, Mexico, Mexico, 
3Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, 4LFB Biomedicaments, Paris, 
France
objeCtives: Maternal Death (MD) is a health public issue in Mexico, the MD Ratio 
(MDR) is 43.2 deaths/100,000 newborns, the Post-Partum Hemorragea (PPH) repre-
sents the second cause of MD (23%), with a higher impact in mexican provinces with 
poor or limited blood products access. The purpose of this study was to estimate 
from the health service provider perspective, the cost-effectiveness in the use of 
Human Fibrinogen (HF) (Clottafact®) in the hematologic treatment of masive PPH 
during limited access of boold products (access after 20 minutes). Methods: A 
decition tree was created to estimate the survival probabilities and costs of PPH 
under a limited blood product access scenario, the use of HF or the use of recom-
binant Factor VII alfa (Factor rVIIa). The effectiveness was obtained from literature. 
The costs were estimated throughout an expert consensus and were expressed in US 
Dollars (exchange rate 1USD/13.0 MXN). The CER and ICER were estimated per saved 
live and a probabilistic sensibility analysis was performed. Results: The average 
cost per treated patient with limited access to blood products was 12,350 USD, with 
HF was $13,182 USD wheras with Factor rVIIa it was $14,526 USD. The survival rate 
was 0.59, 0.98 and 0.93 respectively. The cost per saved life with limited treatment 
was $21,238 USD, with HF was $13,410 and with Factor rVIIa it was $15,552 USD. The 
acceptability curve shows that the use of HF is cost-effective in 65% to 85% of the 
cases with a $3,000 USD willingness to pay limit. ConClusions: Human Fibrinogen 
represents the best treatment alternative for the PPH in Mexican provinces with 
poor access to blood products and it would significantly reduce the MDR in Mexico.
PIH38
Cost EffECtIvEnEss of HystErosCoPIC tubAl stErIlIzAtIon (Hts) 
ComPArEd to lAPArosCoPIC tubAl stErIlIzAtIon (lts) for PErmAnEnt 
bIrtH Control
Yan C., Chuck A.
Institute of Health Economics, Edmonton, AB, Canada
objeCtives: The objective of the study was to assess the cost-effectiveness of 
hysteroscopic tubal sterilization (HTS) for permanent birth control, compared with 
laparoscopic tubal sterilization (LTS). Methods: Cost effectiveness was addressed 
through an economic evaluation using a decision analytic model that compared 
the health benefits and resource expenditures associated with three alternative 
protocols: Calgary HTS protocol, Saskatchewan HTS protocol, and LTS. The analysis 
adopted a payer perspective and considered direct medical service costs to the 
Alberta health system, including costs of physician, hospital and confirmative 
diagnosis. The time horizon for the analysis considered costs from initial surgery 
to follow-up diagnosis up to 6 months post-surgery. Clinical and epidemiological 
data came from a review of literature and expert opinions. Cost data for LTS were 
primarily obtained from provincial administrative databases. Results: Both the 
be cost-effective compared to the most prominent comparators in management of 
infertility in The Netherlands.
PIH33
Cost-EffECtIvEnEss of long-ACtIng rEvErsIblE ContrACEPtIon: lng-
Ius 13.5mg, A low-dosE ContrACEPtIvE lEvonorgEstrEl IntrAutErInE 
systEm vErsus orAl ContrACEPtIvEs
Hassan F.1, Dhanjal J.1, Lowin J.1, Jeddi M.2, Filonenko A.3
1IMS Health, London, UK, 2Bayer Inc., Toronto, ON, Canada, 3Bayer Pharma AG, Berlin, Germany
objeCtives: This study aimed to evaluate the cost-effectiveness of LNG-IUS 13.5mg, 
a low-dose hormonal intrauterine contraceptive system for use up to 3 years, rela-
tive to the most commonly used oral contraceptive (OC) in Canada from a societal 
perspective. Methods: A state-transition model was developed to assess the 
cost-effectiveness of LNG-IUS 13.5mg over 3 years in a cohort of 1,000 women of 
reproductive age (15-44 years). The comparator was a generic version of the 100 
mcg levonorgestrel and 20 mcg ethinyl estradiol OC. The model consisted of three 
mutually exclusive health states: initial contraceptive method, unplanned preg-
nancy (UP) due to contraceptive failure and subsequent contraceptive method, taken 
up following UP or due to discontinuation of the initial method. The subsequent 
contraceptive method was represented by a basket of market-weighted contracep-
tives. Contraceptive failure and discontinuation rates were taken from published 
literature, resource use was estimated from product monographs and unit costs 
were taken from standard Ontario and Quebec cost databases. Analysis from the 
societal perspective allowed the model to incorporate economic costs associated 
with missed work. The key model output was cost per UP avoided. Probabilistic 
sensitivity analyses (PSA) were performed. Results: LNG-IUS 13.5mg dominated 
the OC method, resulting in fewer UP (8 vs. 180) and lower total costs ($665,224 vs. 
$1,102,456), representing a savings of $437,232 over 3 years. Overall savings resulted 
from fewer UP and avoided costs associated with the uptake of the subsequent con-
traceptive method. PSA results indicated a high probability of dominance as all itera-
tions showed LNG-IUS 13.5mg to be more effective and less costly. ConClusions: 
LNG-IUS 13.5mg is an effective contraceptive option that generates savings com-
pared to a generic OC.
PIH34
EConomIC EvAluAtIon of oxytoCIn In unIjECt InjECtIon systEm 
vErsus stAndArd usE of oxytoCIn for tHE PrEvEntIon of PostPArtum 
HEmorrHAgE In lAtIn AmErICA And tHE CArIbbEAn
Pichon riviere A.1, Glujovsky D.2, Garay O.U.3, Augustovski F.3, Ciapponi A.2, Serpa M.1
1Health Economic Evaluations and Technology Assessment at the Institute for Clinical 
Effectiveness and Health Policy, Buenos Aires, Argentina, 2Institute for Clinical Effectiveness and 
Health Policy (IECS), CABA, Argentina, 3Institute for Clinical Effectiveness and Health Policy 
(IECS), Buenos Aires, Argentina
objeCtives: Postpartum hemorrhage (PPH) is a leading cause of maternal death. 
Although the strong evidence showing the efficacy of oxytocin in preventing PPH, its 
use remains suboptimal. The Uniject injection system prefilled with oxytocin (OiU) 
has the potential advantage, due to its ease of use, to increase oxytocin coverage rates 
(OCR). This study objective is to evaluate the cost-effectiveness of OiU in Latin America 
(LAC). Methods: We built an epidemiological model to estimate the impact of replac-
ing oxytocin in ampoules with OiU on the incidence of PPH, quality-adjusted life 
years (QALYs) and costs from a health care perspective. A systematic search for data 
on epidemiology and cost studies was undertaken. A consensus panel among LAC 
experts was performed to quantify the expected increase in OCR as a consequence 
of making OiU available. Deterministic and probabilistic sensitivity analyses were 
performed. Results: In the threshold analysis the minimum required increment in 
the OCR to make OiU a cost-effective strategy ranged from 1.3% in Suriname to 16.2% 
in Haiti. In more than 60% of the countries, the required increment was below 5%. OiU 
could prevent more than 40,000 PPH episodes annually in LAC. In 27% of the countries 
OiU showed to be cost saving. In the remaining 21 countries OiU was associated with 
a net cost increment ($ 0.005 to $0.780 2013 US dollars per delivery). OiU strategy 
ranged from being dominant to having an ICER of $ 9,454 per QALY gained. In the great 
majority of countries these ICERs were below one GDP per capita. ConClusions: 
OiU was cost-saving or very cost-effective in almost all countries. Even if countries 
can achieve only small increases in OCR by incorporating OiU, this strategy could be 
considered an efficient use of resources. These results showed to be robust in the 
sensitivity analysis under a wide range of assumptions and scenarios.
PIH35
tHE Cost-EffECtIvEnEss of AntEnAtAl syPHIlIs sCrEEnIng usIng PoInt-
of-CArE tEstIng In lAtIn AmErICA
Komakech H.1, Muhumuza C.1, Lamorde M.2, Marques E.3, Kuznik A.4
1Makerere University, Kampala, Uganda, 2Infectious Diseases Institute, KAMPALA, Uganda, 
3University of Bristol, Bristol, UK, 4Pfizer
objeCtives: Untreated syphilis in pregnancy is associated with adverse clinical 
outcomes to the infant. In Latin America, roughly three out of every ten women 
are not tested for syphilis during pregnancy. The objective of this analysis was 
to evaluate the cost-effectiveness, budget impact, and potential reduction in 
adverse pregnancy outcomes of antenatal syphilis screening using the recently 
introduced point of care immunochromatographic strip test across 20 countries in 
Latin America. Methods: A previously published cost-effectiveness model was 
adapted to reflect the perspectives of the respective national health care systems. 
Clinical outcomes of infants born to syphilis-infected mothers on the endpoints 
of stillbirth, neonatal death and congenital syphilis were obtained from published 
sources. Treatment was assumed to consist of three injections of benzathine penicil-
lin. Country-specific inputs included the antenatal prevalence of syphilis; annual 
number of live births; proportion of women with at least one antenatal care visit; 
per capita gross national income and estimated hourly nurse wages. Results: In 
all 20 Latin American countries, syphilis screening is highly cost-effective with an 
weighted average cost/DALY averted of US$110 (range: US$10-US$308). Universal 
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to assess, from the governmental perspective, the cost-effectiveness of using QIV 
versus TIV as an influenza vaccination for children under 17 years old. Methods: 
A Markov model was used to assess the cost and effectiveness of QIV and TIV. Cost 
data were obtained from the National Health Insurance claims data. Vaccine effi-
cacy and transition probability of different health states were based on previous 
studies. Outcomes included cases avoided, life-years gained, QALYs gained and the 
corresponding incremental cost-effectiveness ratios (ICERs). The discount rate of 
cost and effectiveness was set at 3.5% and the time horizon used in the model is 100 
years. Results: The avoided influenza-associated outcomes form QIV, compared to 
TIV, and throughout the estimate lifetime were as follows: 251,512 influenza cases 
avoided, 32,355 cases with influenza complications avoided, 254,855 outpatient vis-
its avoided, 3,860 inpatients receiving treatment for complications avoided and 717 
deaths avoided. The ICER of this alternative, compared with TIV, was US$44,231.3 per 
QALY gained. When the herd effect was taken into consideration, the ICER dropped 
to US$30,947.85 per QALY gained. ConClusions: From the governmental perspec-
tive, the QIV of seasonal influenza is associated with favorable cost-effectiveness 
ratios in children under 17 years.
PIH42
A Cost mInImIsAtIon AnAlysIs of gonAdotroPIns for In vItro 
fErtIlIzAtIon ovArIAn stImulAtIon on PrEgnAnCy- And lIvE bIrtH-
bAsEd EndPoInts In gErmAny
Nanguneri S.1, Ezcurra D.1, Cespedes A.1, Xenakis A.2, Beckerman R.2
1EMD Serono, Rockland, MA, USA, 2CBPartners, New York, NY, USA
objeCtives: The purpose of this analysis was to quantify the cost-effectiveness 
of recombinant follitropin alfa (r-hFSH) and highly purified urinary follicle stimu-
lating hormone (uFSH-HP) in the in-vitro fertilization (IVF) process. Methods: 
An Excel-based model estimated the drug cost per pregnancy and drug cost per 
live birth resulting from a hypothetical cohort of 1000 women undergoing IVF in 
Germany. Model inputs were taken from peer-reviewed published literature, and 
used to estimate the number of embryos generated per IU of gonadotropin used 
for ovarian stimulation. The cohort then underwent multiple rounds of embryo 
transfers (ETs) until embryo exhaustion or pregnancy as dictated by literature val-
ues. The obtained pregnancy rates were multiplied by the percentage of live births 
achieved per pregnancy according to the 2012 German IVF Registry to generate 
the live birth analysis. The cost inputs for r-hFSH and for uFSH-HP were ex-factory 
prices provided by Merck Serono affiliates in Germany. Cost inputs were limited to 
the cost of drug, as medical costs associated with the IVF procedure were assumed 
to be equal for both r-hFSH and uFSH-HP, and would not affect the comparison. 
All of the model outputs were age-agnostic and did not take into consideration 
procedural differences amongst fertility clinics, as the referenced clinical studies 
did not provide these details. Results: Treatment with r-hFSH resulted in a cost 
per pregnancy of 173€ (235USD, 10%) (Bergh et al.) and 47€ (64USD, 2%) (Frydman 
et al.) less than treatment with uFSH-HP. The cost per live birth was 622€ (846USD, 
15%) (Bergh et al.) and 312€ (424USD, 6%) (Frydman et al.) less with r-hFSH than for 
uFSH-HP. ConClusions: r-hFSH minimises the cost per pregnancy and cost per 
live birth in Germany. The results of the model demonstrate that r-hFSH represents 
a cost-effective gonadotropin to use for IVF ovarian stimulation.
PIH43
A Cost-mInImIzAtIon AnAlysIs of CArbEtoCIn for tHE PrEvEntIon of 
PostPArtum HEmorrHAgE In CAnAdA
Mills F.1, Siu E.1, Poinas A.C.1, Chamy C.2
1Wyatt Health Management, Oakville, ON, Canada, 2Ferring Pharmaceuticals, Toronto, ON, 
Canada
objeCtives: The objective of this analysis is to demonstrate the economic value of 
Duratocin® in the prevention of postpartum hemorrhage from uterine atony dur-
ing active management of the third stage of labour in elective caesarean section 
delivery. Methods: We analyzed the economic value of Duratocin® (carbetocin) in 
relation to the comparators most commonly encountered in clinical practice, and 
recommended in the clinical practice guidelines of the Society of Obstetricians and 
Gynecologists of Canada. We modeled the treatment pathways as described in the 
guidelines, and also the use of uterotonics encountered in typical Canadian practice, 
i.e. as a second-line intervention. Assuming that the ultimate incidence of postpar-
tum hemorrhage is equal between all treatment strategies, we constructed cost-
minimization models in TreeAge Pro (2013), with a time horizon of 8 hours. Transition 
probabilities were derived from the literature, and costs and resource consumption 
data were obtained from hospital databases and input from health care profession-
als. Results: Duratocin® was shown to be the lowest cost treatment strategy in the 
prevention of postpartum hemorrhage in elective caesarean section delivery using 
either guidelines or typical-use treatment pathways. The total expected cost of the 
carbetocin treatment strategy under the SOGC Guidelines scenario is $22.12, vs. $24.91 
for the oxytocin strategy. In the typical use scenario the results are even clearer, 
with carbetocin providing very substantial cost-savings compared to ergonovine or 
carboprost. ConClusions: These results were robust to all sensitivity analyses in 
the case of the typical-use scenario. In the SOGC Guidelines scenario the results were 
robust to all sensitivity analyses except the dosing of ergonovine.
PIH44
A Cost mInImIsAtIon AnAlysIs of gonAdotroPIns for In vItro 
fErtIlIzAtIon ovArIAn stImulAtIon on ooCytE- And Embryo-bAsEd 
EndPoInts
Nanguneri S.1, Ezcurra D.1, Cespedes A.1, Xenakis A.2, Beckerman R.2
1EMD Serono, Rockland, MA, USA, 2CBPartners, New York, NY, USA
objeCtives: The purpose of this analysis was to quantify the cost-effectiveness of 
recombinant follitropin alfa (r-hFSH) and highly purified human menopausal gonado-
tropin (HP-hMG) in the in-vitro fertilization (IVF) process. Methods: An Excel-based 
model was constructed to estimate the cost per oocyte retrieved, cost per embryo gen-
erated, and cost per optimal chance of live birth for r-hFSH and HP-hMG in Sweden. 
Calgary and Saskatchewan HTS protocols were found to be costly compared to 
LTS with the Calgary protocol being the most costly. The Saskatchewan protocol 
was found to be less costly than the Calgary protocol primarily due to employing 
ultrasound as the initial confirmatory diagnostic which reduces the number of 
Hysterosalpingogram (HSG) procedures conducted compared to the Calgary proto-
col. However, while HTS is more costly than LTS, it was also more effective. The costs 
saved per successful procedure lost by switching from LTS to the Saskatchewan pro-
tocol or the Calgary protocol was $3,588 and $4,789, respectively. This result suggests 
that the Saskatchewan protocol is cost effective compared to the Calgary protocol 
(i.e. within HTS comparison) because the Saskatchewan protocol saves more money 
for a unit of effectiveness lost. ConClusions: The existing evidence suggest that 
compared to LTS, HTS is more costly but also more effective. While replacing eligible 
LTS procedures with HTS will result in costs decision makers will need to determine 
whether the amount of costs outweighs the amount of effectiveness gains.
PIH39
Cost-EffECtIvEnEss AnAlysIs of flosEAl (HAEmostAtIC mAtrIx) As A 
HAEmostAtIC AgEnt In obstEtrIC HAEmorrHAgE In mExICo
Martínez Gaytan V.1, Briones Lara E.1, Soto Molina H.2, Torcida Gonzalez M.1,  
Alvarez Chavez L.1, Barrientos Navarro M.1, Felix Zamudio L.1
1IMSS, Monterrey, Mexico, 2Universidad Autónoma Metropolitana, Mexico City, Mexico
objeCtives: To perform a complete economic evaluation of cost-effectiveness on 
the use of Floseal versus standard treatment for obstetric haemorrhage in Mexican 
patients from the Public Health Sector point of view Methods: An economic analy-
sis was designed using data base from the UMAE 23 Hospital of Gynecology and 
Obstetrics ¨Dr. Ignacio Morones Prieto¨, to compare Floseal and Control (standard 
treatment) in obstetric haemorrhage. The efficiency measure was the percentage 
of patients who avoided surgical re-intervention. Only costs from medical attention 
were used such as: haemostatic agents, hospitalization and surgery. An incremental 
cost-effectiveness analysis was performed, as well as a (deterministic and stochas-
tic) sensitivity analysis, modifying cost and effectiveness of Floseal; and reinforced 
with the statistical analysis and lineal regression to determine de influence of sev-
eral parameters on the total cost. Results: The data base prove that Floseal is a 
more cost-effectiveness option than Control; 100% of patients avoided surgical re-
intervention compared to 46.66% of the Control (p< .0001). Patients that used Floseal 
had less hospitalization time and less time in the intensive care unit with respect 
to patients with standard treatment. And, Floseal in obstetric haemorrhage had 
an average cost per patient of $137,505, while Control group was $237,470 generat-
ing savings of $99,965 per patient. The sensitivity analysis, statistical analysis and 
lineal regression analysis proved the strength of these results. ConClusions: The 
economic evaluation proved that Floseal is an cost-effectiveness and safe option 
with respect to Control, used in obstetric haemorrhage in Mexican patients, hav-
ing a lesser cost while avoiding surgical re-interventions and hospitalization days.
PIH40
PotEntIAl Cost-EffECtIvEnEss of PrEnAtAl dIstrIbutIon of 
mIsoProstol for PrEvEntIon of Post PArtum HEmorrHAgE In ugAndA
Lubinga S.J.1, Atukunda E.2, Ssalongo G.W.3, Babigumira J.B.1
1University of Washington, Seattle, WA, USA, 2Mbarara University of Science and Technology, 
Mbarara, Uganda, 3Mbarara Regional Referral Hospital, Mbarara, Uganda
objeCtives: Prenatal distribution of misoprostol has been advocated as a strategy to 
increase access to uterotonics during the third stage of labor to prevent Post Partum 
Hemorrhage (PPH). The objective of this study was to project the potential cost-effec-
tiveness of this strategy in Uganda from both governmental (payer) and societal per-
spectives. Methods: To compare prenatal misoprostol distribution to the status quo 
(no misoprostol distribution), we developed a decision model that tracked the delivery 
pathways, outcomes and cost of a pregnant woman from the prenatal period to onset 
of labor, delivery without complications or delivery with PPH, and successful treat-
ment or death. Model parameters were derived from the Uganda Demographic and 
Health Survey and the published literature, as well as expert opinion. We computed 
expected probabilities of PPH and death due to PPH, Disability Adjusted Life Years 
(DALYs) and costs. In the incremental analysis, we calculated changes in expected 
probabilities of PPH and death due to PPH, Disability Adjusted Life Years (DALYs) and 
changes in costs. We conducted univariate and probabilistic sensitivity analyses to 
examine robustness of our results. Results: In the base case analysis, the expected 
probabilities of PPH and death due to PPH were lower with prenatal misoprostol dis-
tribution (14.0% versus 16.3% and 1.4% versus 1.7% respectively). Mean DALYs were 
lower with prenatal misoprostol distribution (0.408 versus 0.511). Mean costs were 
lower with prenatal misoprostol distribution both from the governmental ($17.42 
versus $18.27) and societal ($30.02 versus $31.55) perspectives. In the incremental 
analysis, prenatal misoprostol distribution was a dominant strategy i.e. it was both 
less costly and more effective. This result was robust to univariate and probabilistic 
sensitivity analysis. ConClusions: Prenatal distribution of misoprostol is poten-
tially cost-effective in Uganda. It would potentially save lives and money and should 
be considered for national-level scale up for prevention of PPH.
PIH41
Cost-EffECtIvEnEss of QuAdrIvAlEnt vErsus trIvAlEnt InfluEnzA 
vACCInEs for CHIldrEn
Yang M.C., Tan C.H.
National Taiwan University, Taipei, Taiwan
objeCtives: Influenza could cause serious consequences, especially on children. 
The WHO recommended that influenza vaccination of children is the most effective 
means. Trivalent influenza vaccine (TIV), which contains two lineages of influenza 
A virus and one lineage of influenza B virus, is now use as a first-line strategy to 
prevent influenza in Taiwan. However, when the influenza B-lineage included in the 
TIV mismatched with circulating strains, the protection of TIV would be reduced. 
Quadrivalent influenza vaccine (QIV) which includes both influenza B viruses of the 
two circulating lineages is thus proposed as an alternative. The aim of the study was 
